

# Marcelo A Queiroz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7205862/publications.pdf>

Version: 2024-02-01

28  
papers

921  
citations

567281

15  
h-index

552781

26  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1217  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence. <i>European Urology Oncology</i> , 2023, 6, 41-48.	5.4	14
2	Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease. <i>Molecular Imaging and Biology</i> , 2022, 24, 453-463.	2.6	2
3	Prostate Cancer Imaging: What We Already Know and What Is on the Horizon. <i>Radiographics</i> , 2022, 42, E123-E124.	3.3	1
4	Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 186-195.	6.4	20
5	Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. <i>Radiographics</i> , 2021, 41, 120-143.	3.3	27
6	PET/MRI Characterization of Mucinous Versus Nonmucinous Components of Rectal Adenocarcinoma: A Comparison of Tumor Metabolism and Cellularity. <i>American Journal of Roentgenology</i> , 2021, 216, 376-383.	2.2	7
7	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1522-1537.	6.4	6
8	Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer. <i>Radiographics</i> , 2020, 40, 1412-1430.	3.3	17
9	Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. <i>Cancer Imaging</i> , 2020, 20, 23.	2.8	145
10	Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. <i>Radiographics</i> , 2020, 40, 1715-1740.	3.3	65
11	Regorafenib in Patients with Antiangiogenic <sup>Na<sup>+</sup></sup> -ve and Chemotherapy <sup>Refractory</sup> Advanced Colorectal Cancer: Results from a Phase IIb Trial. <i>Oncologist</i> , 2019, 24, 1180-1187.	3.7	19
12	Aberrant Hypermetabolism of Benign Uterine Leiomyoma on 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e413-e414.	1.3	10
13	Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread. <i>Radiographics</i> , 2019, 39, 186-212.	3.3	68
14	Neuro: Head and Neck Oncology. , 2018, , 223-248.		0
15	Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 892-899.	1.5	19
16	Positron emission tomography/magnetic resonance imaging (PET/MRI): An update and initial experience at HC-FMUSP. <i>Revista Da Associação Médica Brasileira</i> , 2018, 64, 71-84.	0.7	5
17	Clinical evaluation of a block sequential regularized expectation maximization reconstruction algorithm in 18F-FDG PET/CT studies. <i>Nuclear Medicine Communications</i> , 2017, 38, 57-66.	1.1	42
18	Hybrid PET/MR: Updated Clinical Use and Potential Applications. <i>Current Radiology Reports</i> , 2016, 4, 1.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e417-e419.	1.3	8
20	Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. <i>BMC Cancer</i> , 2015, 15, 1002.	2.6	42
21	18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT. <i>Nuclear Medicine Communications</i> , 2015, 36, 1165-1173.	1.1	43
22	PET/MR in Cancers of the Head and Neck. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 248-265.	4.6	69
23	PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison. <i>European Radiology</i> , 2015, 25, 2222-2230.	4.5	105
24	Dose Optimization in TOF-PET/MR Compared to TOF-PET/CT. <i>PLoS ONE</i> , 2015, 10, e0128842.	2.5	30
25	Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI. <i>Swiss Medical Weekly</i> , 2015, 145, w14116.	1.6	11
26	Clinical image quality perception and its relation to NECR measurements in PET. <i>EJNMMI Physics</i> , 2014, 1, 103.	2.7	15
27	Use of diffusion-weighted imaging (DWI) in PET/MRI for head and neck cancer evaluation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2212-2221.	6.4	63
28	PET/MRI and PET/CT in follow-up of head and neck cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1066-75.	6.4	68